Terbogrel Explained

Terbogrel (INN^[1]) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes. Terbogrel is an orally available thromboxane A₂ receptor antagonist and a thromboxane A synthase inhibitor.^{[2] [3]} The drug was developed by Boehringer Ingelheim.

A phase 2 clinical trial of terbogrel was discontinued due to its induction of leg pain.^[4]

See also

• Ramatroban

Notes and References

1. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 37 . WHO Drug Information . 1997 . 11 . 1 . 49 . https://web.archive.org/web/20161220045248/http://apps.who.int/medicinedocs/index/assoc/s14162e/s14162e.pdf . dead . December 20, 2016 . 3 December 2016.
2. Guth . BD . Narjes . H . Schubert . HD . Tanswell . P . Riedel . A . Nehmiz . G . Pharmacokinetics and Pharmacodynamics of Terbogrel, a Combined Thromboxane A₂ Receptor and Synthase Inhibitor, in Healthy Subjects . British Journal of Clinical Pharmacology . July 2004 . 58 . 1 . 40–51 . 10.1111/j.1365-2125.2004.02083.x . 15206991 . 1884538.
3. Michaux . C . Norberg . B . Dogné . JM . Durant . F . Masereel . B . Delarge . J . Wouters . J . Terbogrel, a Dual-Acting Agent for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition . Acta Crystallographica . October 2000 . 56 . Pt 10 . 1265–6 . 11025320 . 10.1107/s0108270100009872.
4. Capra V, Bäck M, Angiolillo DJ, Cattaneo M, Sakariassen KS . Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation . Journal of Thrombosis and Haemostasis . 12 . 2 . 126–37 . 2014 . 24298905 . 10.1111/jth.12472 . free .